Francesco Trotta

List of Publications by Year in descending order

65	1,652	279701	302012
papers	citations	23 h-index	39 g-index

71	71	71	2654
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine, 2013, 31, 1246-1254.	1.7	205
2	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands:â€‰ Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D2 Receptors. Journal of Medicinal Chemistry, 2003, 46, 3822-3839.	2.9	90
3	Vasculitis as an adverse event following immunization â€“ Systematic literature review. Vaccine, 2016, 34, 6641-6651.	1.7	87
4	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. International Clinical Psychopharmacology, 2006, 21, 319-336.	0.9	84
5	Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior. Journal of Medicinal Chemistry, 2009, 52, 151-169.	2.9	79
6	Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6015-6026.	1.7	74
7	Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice. Journal of Clinical Oncology, 2011, 29, 2266-2272.	0.8	64
8	Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. European Journal of Clinical Investigation, 2010, 40, 69-86.	1.7	49
9	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. Journal of Medicinal Chemistry, 2014, 57, 9578-9597.	2.9	46
10	Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology, 2008, 19, 1347-1353.	0.6	44
11	Risk of Guillain-BarrÃ© syndrome after 2010â€“2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.	2.5	41
12	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	1.7	41
13	Off-label use of medicines in children: can available evidence avoid useless paediatric trials?. European Journal of Clinical Pharmacology, 2009, 65, 209-216.	0.8	40
14	Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ, The, 2014, 348, g3361-g3361.	3.0	38
15	Novel Atypical Antipsychotic Agents:Â Rational Design, an Efficient Palladium-Catalyzed Route, and Pharmacological Studies. Journal of Medicinal Chemistry, 2005, 48, 1705-1708.	2.9	37
16	How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makersâ€™ views. Annals of Oncology, 2014, 25, 265-269.	0.6	36
17	Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. International Journal of Cardiology, 2016, 203, 217-220.	0.8	36
18	Drug use and upper gastrointestinal complications in children: a case-control study. Archives of Disease in Childhood, 2013, 98, 218-221.	1.0	32

#	Article	IF	Citations
19	Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy, 2019, 123, 595-600.	1.4	30
20	Stevens-Johnson Syndrome Associated with Drugs and Vaccines in Children: A Case-Control Study. PLoS ONE, 2013, 8, e68231.	1.1	29
21	A Multicentric Prospective Incidence Study of Guillain-BarrÃ© Syndrome in Italy. The ITANG Study. Neuroepidemiology, 2015, 45, 90-99.	1.1	27
22	Kawasaki disease and immunisation: A systematic review. Vaccine, 2017, 35, 1770-1779.	1.7	27
23	Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3and Serotonin 5-HT1Aand 5-HT2AReceptors. Journal of Medicinal Chemistry, 2010, 53, 4803-4807.	2.9	25
24	1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structureâ^'Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. Journal of Medicinal Chemistry, 2008, 51, 6614-6618.	2.9	22
25	Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open, 2017, 7, e011637.	0.8	22
26	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Drug Safety, 2019, 42, 1437-1447.	1.4	19
27	Using GRADE methodology to assess innovation of new medicinal products in Italy. British Journal of Clinical Pharmacology, 2020, 86, 93-105.	1.1	18
28	Haematological anticancer drugs in Europe: any added value at the time of approval?. European Journal of Clinical Pharmacology, 2007, 63, 713-719.	0.8	17
29	In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. European Journal of Clinical Pharmacology, 2009, 65, 851-852.	0.8	17
30	Vaccine effectiveness against severe laboratory-confirmed influenza in children: Results of two consecutive seasons in Italy. Vaccine, 2014, 32, 4466-4470.	1.7	17
31	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009â€“2014. Frontiers in Endocrinology, 2018, 9, 95.	1.5	17
32	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open, 2019, 9, e033728.	0.8	17
33	A new anti-cancer drug in the market: Good news for investors or for patients?. European Journal of Cancer, 2008, 44, 1786-1788.	1.3	16
34	Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region. BioDrugs, 2017, 31, 117-124.	2.2	16
35	Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance. British Journal of Clinical Pharmacology, 2021, 87, 1033-1042.	1.1	16
36	Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. Journal of Nephrology, 2018, 31, 321-332.	0.9	15

#	Article	IF	Citations
37	Disclosure of grounds of <scp>E</scp>uropean withdrawn and refused applications: a step forward on regulatory transparency. British Journal of Clinical Pharmacology, 2013, 75, 1149-1151.	1.1	14
38	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clinical Epidemiology, 2018, Volume 10, 203-213.	1.5	12
39	Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. Bone, 2021, 142, 115752.	1.4	11
40	Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open, 2011, 1, e000167-e000167.	0.8	10
41	Intussusception hospitalizations incidence in the pediatric population in Italy: a nationwide cross-sectional study. Italian Journal of Pediatrics, 2016, 42, 89.	1.0	10
42	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Safety, 2020, 43, 1-5.	1.4	10
43	Ongoing pharmacovigilance on vaccines. Pharmacological Research, 2015, 92, 2-5.	3.1	8
44	Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Archives of Disease in Childhood, 2018, 103, 1163-1167.	1.0	8
45	Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open, 2015, 5, e006619-e006619.	0.8	6
46	Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6561-6571.	1.7	6
47	Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study. PLoS ONE, 2017, 12, e0176276.	1.1	6
48	Variables affecting pricing of orphan drugs: the Italian case. Orphanet Journal of Rare Diseases, 2021, 16, 439.	1.2	6
49	Therapeutic indications in oncology: Emerging features and regulatory dynamics. European Journal of Cancer, 2010, 46, 471-475.	1.3	5
50	Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014â€“2019. Frontiers in Medicine, 2022, 9, 820757.	1.2	5
51	The Assessment of the Innovativeness of a New Medicine in Italy. Frontiers in Medicine, 2021, 8, 793640.	1.2	5
52	How medicines are used in Italy: Data from the National Report 2018. Health Policy and Technology, 2020, 9, 32-38.	1.3	4
53	Real world data to identify target population for new CARâ€T therapies. Pharmacoepidemiology and Drug Safety, 2021, 30, 78-85.	0.9	4
54	Generic substitution of antidiabetic drugs in the elderly does not affect adherence. Annali Dell'Istituto Superiore Di Sanita, 2014, 50, 333-40.	0.2	4

#	Article	IF	Citations
55	Italian program for independent research on drugs: 10Âyear follow-up of funded studies in the area of rare diseases. Orphanet Journal of Rare Diseases, 2016, 11, 36.	1.2	3
56	Comparing safety information of biosimilars with their originators: a crossâ€sectional analysis of European risk management plans. British Journal of Clinical Pharmacology, 2018, 84, 738-763.	1.1	3
57	Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 418-423.	0.7	3
58	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. Therapeutic Innovation and Regulatory Science, 2020, 54, 195-199.	0.8	3
59	Antihypertensive drug use during pregnancy: a population based study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 236-43.	0.2	3
60	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. Journal of Clinical Epidemiology, 2018, 101, 5-16.	2.4	2
61	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. BioDrugs, 2020, 34, 55-64.	2.2	2
62	Information needs on precision medicine: a survey of Italian health care professionals. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 316-323.	0.2	2
63	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. Therapeutic Innovation and Regulatory Science, 0, , 216847901882088.	0.8	1
64	The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives. Frontiers in Pharmacology, 2021, 12, 699062.	1.6	1
65	Qual Ã¨ il Giusto Place in Therapy Dell'olmesartan?. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000264.	0.2	0